Insulet (NASDAQ:PODD) Stock Price Target Raised at Leerink Partners

Insulet (NASDAQ:PODD) had its target price boosted by Leerink Partners from $143.00 to $167.00 in a research report released on Thursday morning,Benzinga reports. Leerink Partners currently has a market perform rating on the medical instruments supplier’s stock.

PODD has been the subject of several other research reports. Benchmark decreased their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. TD Cowen reissued a “hold” rating on shares of Insulet in a research report on Wednesday. Sanford C. Bernstein increased their price objective on shares of Insulet from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company boosted their price target on Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Hold” and an average target price of $192.36.

Insulet Stock Performance

Insulet stock opened at $156.12 on Thursday. The company has a market cap of $10.83 billion, a PE ratio of 25.43, a PEG ratio of 1.25 and a beta of 1.06. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company’s 50-day moving average is $141.91 and its two-hundred day moving average is $177.34.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same quarter in the prior year, the firm earned $1.24 earnings per share. The business’s quarterly revenue was up 19.2% on a year-over-year basis. Equities analysts anticipate that Insulet will post 6.76 earnings per share for the current year.

Hedge Funds Weigh In On Insulet

A number of institutional investors have recently modified their holdings of the company. Fifth Third Bancorp increased its stake in Insulet by 21.3% in the 3rd quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier’s stock worth $8,421,000 after acquiring an additional 11,334 shares during the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of Insulet by 22.5% in the 3rd quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier’s stock worth $545,000 after buying an additional 768 shares during the last quarter. Ritholtz Wealth Management purchased a new position in Insulet in the third quarter worth $276,000. Jacobi Capital Management LLC purchased a new position in Insulet in the third quarter worth $40,000. Finally, New York Life Investment Management LLC raised its position in Insulet by 91.5% during the third quarter. New York Life Investment Management LLC now owns 21,015 shares of the medical instruments supplier’s stock valued at $2,742,000 after purchasing an additional 10,042 shares in the last quarter.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.